image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 25.0
-6.05 %
$ 1.19 B
Market Cap
8.17
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMPH stock under the worst case scenario is HIDDEN Compared to the current market price of 25 USD, Amphastar Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMPH stock under the base case scenario is HIDDEN Compared to the current market price of 25 USD, Amphastar Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMPH stock under the best case scenario is HIDDEN Compared to the current market price of 25 USD, Amphastar Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMPH

image
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
713 M REVENUE
10.62%
205 M OPERATING INCOME
4.28%
160 M NET INCOME
15.98%
213 M OPERATING CASH FLOW
16.28%
-125 M INVESTING CASH FLOW
80.75%
-81 M FINANCING CASH FLOW
-17.83%
187 M REVENUE
-0.98%
45.1 M OPERATING INCOME
-20.87%
38 M NET INCOME
-6.10%
29 M OPERATING CASH FLOW
-51.60%
-35.7 M INVESTING CASH FLOW
-3.16%
-33.8 M FINANCING CASH FLOW
-48.33%
Balance Sheet Amphastar Pharmaceuticals, Inc.
image
Current Assets 534 M
Cash & Short-Term Investments 222 M
Receivables 136 M
Other Current Assets 176 M
Non-Current Assets 1.04 B
Long-Term Investments 11 M
PP&E 345 M
Other Non-Current Assets 688 M
14.05 %8.64 %11.17 %21.85 %43.60 %Total Assets$1.6b
Current Liabilities 174 M
Accounts Payable 30.5 M
Short-Term Debt 7.04 M
Other Current Liabilities 136 M
Non-Current Liabilities 671 M
Long-Term Debt 41.9 M
Other Non-Current Liabilities 630 M
3.61 %16.12 %4.96 %74.49 %Total Liabilities$845.2m
EFFICIENCY
Earnings Waterfall Amphastar Pharmaceuticals, Inc.
image
Revenue 713 M
Cost Of Revenue 339 M
Gross Profit 374 M
Operating Expenses 168 M
Operating Income 205 M
Other Expenses 45.9 M
Net Income 160 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00713m(339m)374m(168m)205m(46m)160mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
52.45% GROSS MARGIN
52.45%
28.82% OPERATING MARGIN
28.82%
22.38% NET MARGIN
22.38%
21.78% ROE
21.78%
10.11% ROA
10.11%
12.28% ROIC
12.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amphastar Pharmaceuticals, Inc.
image
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 160 M
Depreciation & Amortization 53 M
Capital Expenditures -41 M
Stock-Based Compensation 24.4 M
Change in Working Capital 0
Others -5.6 M
Free Cash Flow 172 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amphastar Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AMPH of $56.3 , with forecasts ranging from a low of $32 to a high of $71 .
AMPH Lowest Price Target Wall Street Target
32 USD 28.00%
AMPH Average Price Target Wall Street Target
56.3 USD 125.33%
AMPH Highest Price Target Wall Street Target
71 USD 184.00%
Price
Max Price Target
Min Price Target
Average Price Target
75757070656560605555505045454040353530302525May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Amphastar Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
159 K USD 2
3-6 MONTHS
2.35 M USD 4
6-9 MONTHS
1.67 M USD 4
9-12 MONTHS
314 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. accessnewswire.com - 2 weeks ago
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. ("IMS"), a subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar") received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration ("FDA"). accessnewswire.com - 3 weeks ago
New Strong Sell Stocks for March 24th AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025. zacks.com - 3 weeks ago
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. accessnewswire.com - 1 month ago
Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AMPH NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. accessnewswire.com - 1 month ago
AMPH ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. Shareholders Who Lost Money NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. accessnewswire.com - 1 month ago
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents. benzinga.com - 1 month ago
Amphastar: Earnings Miss, Margins Drop Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results. fool.com - 1 month ago
Amphastar Pharmaceuticals, Inc. Being Investigated on Behalf of Amphastar Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. accessnewswire.com - 1 month ago
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.92 per share, missing the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.88 per share a year ago. zacks.com - 1 month ago
8. Profile Summary

Amphastar Pharmaceuticals, Inc. AMPH

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.19 B
Dividend Yield 0.00%
Description Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Contact 11570 6th Street, Rancho Cucamonga, CA, 91730 https://www.amphastar.com
IPO Date June 25, 2014
Employees 2028
Officers Mr. William J. Peters M.B.A. Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director Tony Marrs M.B.A., M.P.H., M.S. Executive Vice President of Regulatory Affairs & Clinical Operations Dr. Yongfeng Zhang Ph.D. Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director Mr. Jacob Liawatidewi M.B.A. Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Mr. Dan Dischner M.B.A. Senior Vice President of Human Resources & Corporate Communication Mr. Rong Zhou M.S. Senior EVice President of Production & EVP of Scientific Affairs Dr. Ziping Luo Ph.D. Chairman of the Board, Chief Scientist & Chief Operating Officer